Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4794 - Comparing Metastatic (M) Young Onset (YO) Colorectal Cancer (CRC) with Average Onset (AO): Are They Do They Differ Clinical and Genetically?

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Gustavo Dos Santos Fernandes

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

G. Dos Santos Fernandes1, W. Chatila1, R. Yaeger1, R. Mendelsohn1, Z. Stadler1, N.H. Segal2, A. Varghese3, D. Reidy4, L. Diaz5, J. Shia6, E. Vakiani6, J. Hechtman6, N. Schultz7, M. Berger6, D. Hyman3, D. Solit8, L. Saltz2, J. Garcia Aguilar9, A. Cercek10

Author affiliations

  • 1 Gi Medical Oncology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 2 Gastrointestinal Oncology Service, Department Of Medicine, Memorial Sloan Kettering Cancer Center, NY 10065 - New York/US
  • 3 Medicine, MSKCC, New York/US
  • 4 Medicine, MSKCC, NEw YOrk/US
  • 5 Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York City/US
  • 6 Pathology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 7 The Nikolaus Schultz Lab, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 8 Medicine, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 9 Surgery, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 10 Medicine, Memorial Sloan Kettering Cancer Center, 10022 - New York/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4794

Background

The incidence of colorectal cancer in patients(pts) under the age of 50 has been steadily on rising over the last two decades. This is in sharp contrast to average onset CRC where there has been a decline. Little is known about clinical behavior and biology of metastatic CRC in the growing YO population.

Methods

We defined YO as < 45 yo and AO as > 50 yo. To better understand the differences in biology of early onset rectal tumors, we tabulated the clinical characteristics, genomics using next generation sequencing(MSK-IMPACT), treatments and outcomes in 175 metastatic pts with EO CRC, treated at Memorial Sloan Kettering Cancer Center between 2014 and 2017 and compared these cases to a cohort of AO M CRC cases (n = 413) with CRC related Hereditary syndromes such as Lynch Syndrome and inflammatory bowel disease were excluded.

Results

We analyzed 175 in the YO cohort. Age at diagnosis was between 17-35yo in 46 and between 36-45 in 129 pts. Among YO patients, there were 50.2% males, 27.7% smokers and the median BMI was 25.5. Comparing to AO, YO pts have significantly less right sided tumors (22.8% vs 33%; p = 0.01). Treatment choices did not differ among YO vs AO groups; systemic chemotherapy (46.7% vs 42.6%; p = 0.40) and metastasectomy (54.6 vs 49.4; p = 0.33). Overall survival was 59months in the YO vs 63.9 for the AO (p = 0.194). Among genetic characteristics mutational burden and copy number comparison showed no significant differences between the groups.

Conclusions

Our series describes a comprehensive clinical and genomic profile of EO mCRC. In contrast to prior reports YO does not appear to be associated with more aggressive disease and there was no difference in treatment modalities. Detailed genomic and clinical characteristics will be presented.

Clinical trial identification

Legal entity responsible for the study

Andrea Cercek.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.